Search

Your search keyword '"van der Hoeven, Bas L."' showing total 33 results
Start Over Author "van der Hoeven, Bas L." Search Limiters Academic (Peer-Reviewed) Journals
33 results on '"van der Hoeven, Bas L."'

5. Peak and Fixed-Time High-Sensitive Troponin for Prediction of Infarct Size, Impaired Left Ventricular Function, and Adverse Outcomes in Patients With First ST-Segment Elevation Myocardial Infarction Receiving Percutaneous Coronary Intervention

Author

Boden, Helèn, Ahmed, Tarek A.N., Velders, Matthijs A., van der Hoeven, Bas L., Hoogslag, Georgette E., Bootsma, Marianne, le Cessie, Saskia, Cobbaert, Christa M., Delgado, Victoria, van der Laarse, Arnoud, and Schalij, Martin J.

Published
2013
Full Text
View/download PDF

11. Sirolimus-Eluting Stents Versus Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction: 9-Month Angiographic and Intravascular Ultrasound Results and 12-Month Clinical Outcome: Results From the MISSION! Intervention Study

Author

van der Hoeven, Bas L., Liem, Su-San, Jukema, J. Wouter, Suraphakdee, Navin, Putter, Hein, Dijkstra, Jouke, Atsma, Douwe E., Bootsma, Marianne, Zeppenfeld, Katja, Oemrawsingh, Pranobe V., van der Wall, Ernst E., and Schalij, Martin J.

Published
2008
Full Text
View/download PDF

19. Prognosis of complete versus incomplete revascularisation of patients with STEMI with multivessel coronary artery disease: an observational study.

Author

UCL - (SLuc) Service d'endocrinologie et de nutrition, Dimitriu-Leen, Aukelien C, Hermans, Michel, Veltman, Caroline E, van der Hoeven, Bas L, van Rosendael, Alexander R, van Zwet, Erik W, Schalij, Martin J, Delgado, Victoria, Bax, Jeroen J, Scholte, Arthur J H A, UCL - (SLuc) Service d'endocrinologie et de nutrition, Dimitriu-Leen, Aukelien C, Hermans, Michel, Veltman, Caroline E, van der Hoeven, Bas L, van Rosendael, Alexander R, van Zwet, Erik W, Schalij, Martin J, Delgado, Victoria, Bax, Jeroen J, and Scholte, Arthur J H A

Abstract

The best strategy in patients with acute ST-segment elevation myocardial infarction (STEMI) with multivessel coronary artery disease (CAD) regarding completeness of revascularisation of the non-culprit lesion(s) is still unclear. To establish which strategy should be followed, survival rates over a longer period should be evaluated. The aim of this study was to investigate whether complete revascularisation, compared with incomplete revascularisation, is associated with reduced short-term and long-term all-cause mortality in patients with first STEMI and multivessel CAD. This retrospective study consisted of 518 patients with first STEMI with multivessel CAD. Complete revascularisation (45%) was defined as the treatment of any significant coronary artery stenosis (≥70% luminal narrowing) during primary or staged percutaneous coronary intervention prior to discharge. The primary end point was all-cause mortality. Incomplete revascularisation was not independently associated with 30-day all-cause mortality in patients with acute first STEMI and multivessel CAD (OR 1.98; 95% CI 0.62to6.37; p=0.25). During a median long-term follow-up of 6.7 years, patients with STEMI with multivessel CAD and incomplete revascularisation showed higher mortality rates compared with patients who received complete revascularisation (24% vs 12%, p<0.001), and these differences remained after excluding the first 30 days. However, in multivariate analysis, incomplete revascularisation was not independently associated with increased all-cause mortality during long-term follow-up in the group of patients with STEMI who survived the first 30 days post-STEMI (HR 1.53 95% CI 0.89-2.61, p=0.12). In patients with acute first STEMI and multivessel CAD, incomplete revascularisation compared with complete revascularisation was not independently associated with increased short-term and long-term all-cause mortality.

Published
2017

20. Prognosis of complete versus incomplete revascularisation of patients with STEMI with multivessel coronary artery disease: an observational study

Author

Dimitriu-Leen, Aukelien C, primary, Hermans, Maaike P J, additional, Veltman, Caroline E, additional, van der Hoeven, Bas L, additional, van Rosendael, Alexander R, additional, van Zwet, Erik W, additional, Schalij, Martin J, additional, Delgado, Victoria, additional, Bax, Jeroen J, additional, and Scholte, Arthur J H A, additional

Published
2017
Full Text
View/download PDF

24. Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial

Author

Boden, Helèn, primary, van der Hoeven, Bas L., additional, Liem, Su-San, additional, Atary, Jael Z., additional, Cannegieter, Suzanne C., additional, Atsma, Douwe E., additional, Bootsma, Marianne, additional, Jukema, J. Wouter, additional, Zeppenfeld, Katja, additional, Oemrawsingh, Pranobe V., additional, van der Wall, Ernst E., additional, and Schalij, Martin J., additional

Published
2012
Full Text
View/download PDF

27. Myocardial Infarction Occurs with a Similar 24 h Pattern in the 4G/5G Versions of Plasminogen Activator Inhibitor-1

Author

Bergheanu, Sandrin C., primary, Bergheanu, Sandrin C., additional, Pons, Douwe, additional, Jukema, J. Wouter, additional, van der Hoeven, Bas L., additional, Liem, Su-San, additional, Vandenbroucke, Jan P., additional, Rosendaal, Frits R., additional, le Cessie, Saskia, additional, Schalij, Martin J., additional, and van der Bom, Johanna G., additional

Published
2009
Full Text
View/download PDF

28. CCL3 (MIP-1α) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events

Author

de Jager, Saskia C.A., primary, Kraaijeveld, Adriaan O., additional, Grauss, Robert W., additional, de Jager, Wilco, additional, Liem, Su-San, additional, van der Hoeven, Bas L., additional, Prakken, Berent J., additional, Putter, Hein, additional, van Berkel, Theo J.C., additional, Atsma, Douwe E., additional, Schalij, Martin J., additional, Jukema, J. Wouter, additional, and Biessen, Erik A.L., additional

Published
2008
Full Text
View/download PDF

30. Sirolimus-Eluting Stents Versus Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction: 9-Month Angiographic and Intravascular Ultrasound Results and 12-Month Clinical Outcome Results From the MISSION! Intervention Study

Author

van der Hoeven, Bas L., Liem, Su-San, Jukema, J. Wouter, Suraphakdee, Navin, Putter, Hein, Dijkstra, Jouke, Atsma, Douwe E., Bootsma, Marianne, Zeppenfeld, Katja, Oemrawsingh, Pranobe V., van der Wall, Ernst E., and Schalij, Martin J.

Subjects
surgical procedures, operative, cardiovascular diseases
Abstract

ObjectivesOur purpose was to evaluate the efficacy and safety of drug-eluting stents in the setting of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI).BackgroundThere is inconsistent and limited evidence about the efficacy and safety of drug-eluting stents in STEMI patients.MethodsA single-blind, single-center, randomized study was performed to compare bare-metal stents (BMS) with sirolimus-eluting stents (SES) in 310 STEMI patients. The primary end point was in-segment late luminal loss (LLL) at 9 months. Secondary end points included late stent malapposition (LSM) at 9 months as determined by intravascular ultrasound imaging and clinical events at 12 months.ResultsIn-segment LLL was 0.68 ± 0.57 mm in the BMS group and 0.12 ± 0.43 mm in the SES group with a mean difference of 0.56 mm, 95% confidence interval 0.43 to 0.68 mm (p < 0.001). Late stent malapposition at 9 months was present in 12.5% BMS patients and in 37.5% SES patients (p < 0.001). Event-free survival at 12 months was 73.6% in BMS patients and 86.0% in SES patients (p = 0.01). The target-vessel-failure-free survival was 84.7% in the BMS group and 93.0% in the SES group (p = 0.02), mainly because of a higher target lesion revascularization rate in BMS patients (11.3% vs. 3.2%; p = 0.006). Rates of death, myocardial infarction, and stent thrombosis were not different.ConclusionsSirolimus-eluting stent implantation in STEMI patients is associated with a favorable midterm clinical and angiographic outcome compared with treatment with BMS. However, LSM raises concern about the long-term safety of SES in STEMI patients (MISSION!; ISRCTN62825862).

Full Text
View/download PDF

31. Stent Malapposition After Sirolimus-Eluting and Bare-Metal Stent Implantation in Patients with ST-Segment Elevation Myocardial Infarction Acute and 9-Month Intravascular Ultrasound Results of the MISSION! Intervention Study

Author

van der Hoeven, Bas L., Liem, Su-San, Dijkstra, Jouke, Bergheanu, Sandrin C., Putter, Hein, Antoni, M. Louisa, Atsma, Douwe E., Bootsma, Marianne, Zeppenfeld, Katja, Jukema, J. Wouter, and Schalij, Martin J.

Subjects
education
Abstract

ObjectivesAcute and late stent malapposition (SM) after bare-metal stents (BMS) and sirolimus-eluting stents (SES) in ST-segment elevation myocardial infarction patients were studied.BackgroundStent thrombosis may be caused by SM after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction patients.MethodsPost-procedure and follow-up intravascular ultrasound data were available in 184 out of 310 patients (60%; 104 SES, 80 BMS) included in the MISSION! Intervention Study. To determine the contribution of remodeling and changes in plaque burden to the change in lumen cross-sectional area (CSA) at SM sites, the change in lumen CSA (follow-up minus post-lumen CSA) was related to the change in external elastic membrane CSA (remodeling) and change in plaque and media CSA (plaque burden).ResultsAcute SM was found in 38.5% SES patients and 33.8% BMS patients (p = 0.51), late SM in 37.5% SES patients and 12.5% BMS patients (p < 0.001). Acquired SM was found in 25.0% SES patients and 5.0% BMS patients (p < 0.001). Predictors of acute SM were reference diameter (SES: odds ratio [OR] 3.49, 95% confidence interval [CI] 1.29 to 9.43; BMS: OR 28.8, 95% CI 4.25 to 94.5) and balloon pressure (BMS: OR 0.74, 95% CI 0.58 to 0.94). Predictors of late SM were diabetes mellitus (SES: OR 0.16, 95% CI 0.02 to 1.35), reference diameter (BMS: OR 19.2, 95% CI 2.64 to 139.7), and maximum balloon pressure (BMS: OR 0.74, 95% CI 0.55 to 1.00). Change in lumen CSA was related to change in external elastic membrane CSA (R = 0.73, 95% CI 0.62 to 0.84) after SES implantation and to change in plaque and media CSA (R = −0.62, 95% CI −0.77 to −0.46) after BMS implantation. After SES implantation, acquired SM was caused by positive remodeling in 84% and plaque reduction in 16% of patients.ConclusionsAcute SM was common after SES and BMS stent implantation in ST-segment elevation myocardial infarction patients. After SES implantation, late acquired SM is common and generally caused by positive remodeling. (The MISSION! Intervention Study, ISRCTN62825862)

Full Text
View/download PDF

32. Impact of sirolimus-eluting stent implantation compared to bare-metal stent implantation for acute myocardial infarction on coronary plaque composition at nine months follow-up: a Virtual Histology intravascular ultrasound analysis. Results from the Leiden MISSION! intervention study.

Author

Atary JZ, Bergheanu SC, van der Hoeven BL, Atsma DE, Bootsma M, van der Kley F, Zeppenfeld K, Jukema JW, and Schalij MJ

Subjects
Adult, Aged, Angioplasty, Balloon, Coronary adverse effects, Coronary Angiography, Coronary Artery Disease complications, Coronary Artery Disease diagnostic imaging, Female, Humans, Hyperplasia, Male, Middle Aged, Myocardial Infarction diagnostic imaging, Myocardial Infarction etiology, Prosthesis Design, Time Factors, Treatment Outcome, Angioplasty, Balloon, Coronary instrumentation, Cardiovascular Agents administration & dosage, Coronary Artery Disease therapy, Drug-Eluting Stents, Metals, Myocardial Infarction therapy, Sirolimus administration & dosage, Stents, Ultrasonography, Interventional
Abstract

Aims: To evaluate effects of sirolimus-eluting stents (SES) compared to bare-metal stents (BMS) at stent edges in patients with acute myocardial infarction (AMI)., Methods and Results: Clinical, angiographic, intravascular ultrasound (lVUS) and virtual histology (VH)-IVUS results were obtained and analysed in 20 SES and 20 BMS AMI patients at the index procedure and at nine months follow-up. Quantitative angiography and IVUS showed a trend toward decreases in mean lumen diameter, vessel volume, minimum lumen area and mean lumen area at both stent edges of BMS, and at the proximal edge of SES. At the distal stent edge, a significant difference between BMS and SES treated patients in mean lumen area was found (D-0.8+/-1.6 mm2 versus D0.2+/-0.8 mm2 respectively, p=0.04). Furthermore, in-stent SES had a larger lumen volume (SES: 167.7+/-59.2 mm3 versus BMS: 125.1+/-43.8 mm3; p=0.02) and less neointima volume (7.3+/-9.1 mm3 versus 53.2+/-35.1 mm3; p<0.001). Neither SES nor BMS demonstrated a significant effect on plaque composition at follow-up VH-IVUS analysis., Conclusions: A significant difference between SES and BMS treated patients was observed with respect to mean lumen diameter distal to the stented segment which suggests a downstream effect of sirolimus elution.

Published
2009
Full Text
View/download PDF

33. CCL3 (MIP-1 alpha) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events.

Author

de Jager SC, Kraaijeveld AO, Grauss RW, de Jager W, Liem SS, van der Hoeven BL, Prakken BJ, Putter H, van Berkel TJ, Atsma DE, Schalij MJ, Jukema JW, and Biessen EA

Subjects
Acute Coronary Syndrome blood, Aged, Angina, Unstable blood, Animals, Chemokine CCL3 blood, Cohort Studies, Disease Models, Animal, Female, Forecasting, Humans, Male, Mice, Middle Aged, Myocardial Infarction blood, Myocardial Ischemia blood, Pilot Projects, Prognosis, Prospective Studies, Acute Coronary Syndrome diagnosis, Chemokine CCL3 biosynthesis, Myocardial Ischemia diagnosis
Abstract

As chemokines are considered instrumental in thrombotic plaque rupture and erosion as well as in ischemia-reperfusion injury processes, we aimed to identify previously unknown chemokines associated with acute coronary syndromes. Plasma of 44 patients with acute myocardial infarction (AMI) and 22 controls were profiled for a panel of chemokines by multiplex analysis. Levels of CCL3 were prospectively verified in 54 patients with unstable angina pectoris (UAP). An AMI mouse model was used to assess the relationship between differentially expressed chemokines and myocardial ischemia. CCL3 levels were significantly elevated in AMI vs. controls (P=0.02) albeit, that adjustment for confounding factors attenuated this association. In support of a direct association with cardiac ischemia CCL3 levels were also seen to be elevated in patients with UAP at baseline and significantly down-regulated after 180 days (P<0.001). Importantly, baseline upper quartile levels were strongly correlated with future acute coronary syndromes (Likelihood Ratio 11.5; P<0.01). Furthermore circulating levels of CCL3 were significantly enhanced after AMI in mice (P=0.02), while CCR5(+) T-cell numbers were increased as well, suggestive of CCL3 driven T-cell homing towards the ischemic area. CCL3 levels are elevated during ACS and released upon ischemia. Since CCL3 specifically predicts future cardiovascular events, it may serve as a predictive biomarker.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results